[go: up one dir, main page]

AR110056A2 - Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos - Google Patents

Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos

Info

Publication number
AR110056A2
AR110056A2 ARP170103141A ARP170103141A AR110056A2 AR 110056 A2 AR110056 A2 AR 110056A2 AR P170103141 A ARP170103141 A AR P170103141A AR P170103141 A ARP170103141 A AR P170103141A AR 110056 A2 AR110056 A2 AR 110056A2
Authority
AR
Argentina
Prior art keywords
chemiosensory
ligand
themselves
modulation
receivers related
Prior art date
Application number
ARP170103141A
Other languages
English (en)
Original Assignee
Senomyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senomyx Inc filed Critical Senomyx Inc
Publication of AR110056A2 publication Critical patent/AR110056A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

Reivindicación 1: Un compuesto, excluyendo su uso terapéutico, seleccionado del grupo que consiste en los compuestos del grupo de fórmulas (1), o una sal del mismo.
ARP170103141A 2007-06-08 2017-11-10 Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos AR110056A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/760,592 US9603848B2 (en) 2007-06-08 2007-06-08 Modulation of chemosensory receptors and ligands associated therewith

Publications (1)

Publication Number Publication Date
AR110056A2 true AR110056A2 (es) 2019-02-20

Family

ID=40096447

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP170103140A AR110055A2 (es) 2007-06-08 2017-11-10 Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos
ARP170103139A AR110054A2 (es) 2007-06-08 2017-11-10 Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos
ARP170103138A AR110053A2 (es) 2007-06-08 2017-11-10 Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos
ARP170103141A AR110056A2 (es) 2007-06-08 2017-11-10 Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ARP170103140A AR110055A2 (es) 2007-06-08 2017-11-10 Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos
ARP170103139A AR110054A2 (es) 2007-06-08 2017-11-10 Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos
ARP170103138A AR110053A2 (es) 2007-06-08 2017-11-10 Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos

Country Status (2)

Country Link
US (1) US9603848B2 (es)
AR (4) AR110055A2 (es)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
KR20130087054A (ko) 2006-04-04 2013-08-05 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5869222B2 (ja) 2008-01-04 2016-02-24 インテリカイン， エルエルシー 特定の化学的実体、組成物および方法
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
CA3034994A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
EP3085699B1 (en) 2008-07-31 2022-03-02 Firmenich Incorporated Processes for making sweet taste enhancers
US8609173B2 (en) 2008-07-31 2013-12-17 Senomyx Inc. Compositions comprising sweetness enhancers and methods of making them
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
JPWO2010041711A1 (ja) * 2008-10-09 2012-03-08 杏林製薬株式会社 イソキノリン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
JP5819195B2 (ja) 2008-10-16 2015-11-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 融合環ヘテロアリールキナーゼ阻害剤
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP2012506912A (ja) 2008-11-04 2012-03-22 ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション アテローム硬化症、メタボリックシンドロームおよびそれらの症状を予防および処置するためのｄ−タガトースベースの組成物および方法
WO2010103306A1 (en) * 2009-03-10 2010-09-16 Astrazeneca Uk Limited Benzimidazole derivatives and their use as antivaral agents
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
CN102481276A (zh) 2009-04-20 2012-05-30 埃尔舍利克斯治疗公司 基于化学感受受体配体的治疗法
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
CN104945420A (zh) 2009-06-29 2015-09-30 因塞特公司 作为pi3k抑制剂的嘧啶酮类
LT3575288T (lt) 2009-09-03 2021-12-10 Bristol-Myers Squibb Company Chinazolinai kaip kalio jonų kanalų inhibitoriai
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
WO2011056566A2 (en) * 2009-10-26 2011-05-12 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
AR079529A1 (es) * 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
US8759359B2 (en) * 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
US8592592B2 (en) 2010-04-02 2013-11-26 Senomyx, Inc. Sweet flavor modifier
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
CN106107406B (zh) * 2010-08-12 2020-06-09 弗门尼舍公司 提高甜味增强剂的稳定性的方法和包含稳定的甜味增强剂的组合物
WO2012054523A2 (en) * 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
CA2823397C (en) 2011-01-07 2020-03-10 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
MX347708B (es) 2011-01-10 2017-05-09 Infinity Pharmaceuticals Inc Proceso para preparar isoquinolinonas y formas solidas de isoquinolinonas.
EP2678018A4 (en) 2011-02-23 2015-09-30 Intellikine Llc COMBINATION OF CHINESE HEMMER AND USES THEREOF
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CN103946226A (zh) 2011-07-19 2014-07-23 无限药品股份有限公司 杂环化合物及其应用
AU2012295255B2 (en) * 2011-08-12 2016-04-21 Senomyx, Inc. Sweet flavor modifier
HK1199725A1 (en) 2011-08-29 2015-07-17 无限药品股份有限公司 Heterocyclic compounds and uses thereof
AR087760A1 (es) 2011-09-02 2014-04-16 Incyte Corp Heterociclilaminas como inhibidores de pi3k
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
JP5914667B2 (ja) 2011-09-22 2016-05-11 ファイザー・インク ピロロピリミジンおよびプリン誘導体
JO3398B1 (ar) 2011-12-22 2019-10-20 Novartis Ag مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP6551936B2 (ja) 2012-08-06 2019-07-31 セノミックス インコーポレイテッドＳｅｎｏｍｙｘ， Ｉｎｃ． 甘味香味修飾因子
WO2014052669A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
US9290514B2 (en) 2013-07-08 2016-03-22 Incyte Holdings Corporation Tricyclic heterocycles as BET protein inhibitors
HUE057734T2 (hu) 2013-10-04 2022-06-28 Infinity Pharmaceuticals Inc Heterociklusos vegyületek és alkalmazásuk
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10266488B2 (en) 2013-10-10 2019-04-23 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
CA2943363A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
EA034972B1 (ru) 2014-04-23 2020-04-13 Инсайт Корпорейшн 1h-пирроло[2,3-c]пиридин-7(6h)-оны в качестве ингибиторов белков bet
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
CN106456592B (zh) 2014-06-27 2019-06-18 味之素株式会社 甜味受体拮抗剂
EP3194406B8 (en) 2014-09-15 2021-03-31 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2963901A1 (en) 2014-11-07 2016-05-12 Senomyx, Inc. Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers
PT3831833T (pt) 2015-02-27 2023-02-06 Incyte Corp Processos para a preparação de um inibidor pi3k
MY188211A (en) 2015-03-04 2021-11-24 Gilead Sciences Inc Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN105232565B (zh) * 2015-08-13 2017-12-08 北京农学院 罗汉果皂苷或其药学上可接受的盐在制备肿瘤放射增敏剂中的应用
EP3350183B1 (en) 2015-09-14 2025-04-02 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
AR106520A1 (es) 2015-10-29 2018-01-24 Incyte Corp Forma sólida amorfa de un inhibidor de proteína bet
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PT3472157T (pt) 2016-06-20 2023-05-30 Incyte Corp Formas sólidas cristalinas de um inibidor bet
MX391135B (es) 2016-06-24 2025-03-21 Infinity Pharmaceuticals Inc Terapias de combinacion.
MA46093A (fr) 2016-09-02 2021-05-19 Gilead Sciences Inc Composés modulateurs du recepteur de type toll
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
CN118955430A (zh) 2016-09-21 2024-11-15 国际人造丝公司 乙酰舒泛钾组合物和其生产方法
EP3319949B1 (en) 2016-09-21 2020-07-22 Celanese International Corporation Acesulfame potassium compositions and processes for producing same
US10029998B2 (en) 2016-09-21 2018-07-24 Celanese International Corporation Acesulfame potassium compositions and processes for producing same
PT3322695T (pt) 2016-09-21 2020-10-13 Celanese Int Corp Composições de acessulfame de potássio e processos para produzir o mesmo
BR112019026452A2 (pt) 2017-06-13 2020-07-14 Glaxosmithkline Intellectual Property Development Limited compostos químicos como inibidores de h-pgds
KR102884803B1 (ko) 2018-06-01 2025-11-12 인사이트 코포레이션 Pi3k 관련 장애의 치료를 위한 투여 요법
MX2021001193A (es) 2018-08-07 2021-04-28 Firmenich Incorporated 2,2-dioxidos de 4-amino-1h-benzo[c][1,2,6]tiadiazina 5-sustituidos y formulaciones y usos de los mismos.
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
US11534441B2 (en) 2020-01-15 2022-12-27 Blueprint Medicines Corporation MAP4K1 inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022155667A1 (en) 2021-01-15 2022-07-21 Firmenich Incorporated Sweetener compositions comprising mogrosides and uses thereof
US20240090547A1 (en) 2021-01-15 2024-03-21 Firmenich Incorporated Sweetener compositions comprising mogrosides and uses thereof
US20240188613A1 (en) 2021-01-15 2024-06-13 Firmenich Incorporated Sweetener compositions comprising mogrosides and uses thereof
TW202321237A (zh) 2021-07-14 2023-06-01 美商纜圖藥品公司 Ｍａｐ４ｋ１抑制劑
EP4472947A1 (en) 2022-03-07 2024-12-11 Firmenich Incorporated Sweetener compositions
JP2025507547A (ja) 2022-03-10 2025-03-21 フイルメニツヒ ソシエテ アノニム 甘味料組成物
JP2025510598A (ja) 2022-04-11 2025-04-15 フイルメニツヒ ソシエテ アノニム 甘味料組成物
NL2033363B1 (en) 2022-10-20 2024-05-08 Univ Eindhoven Tech A non-aqueous redox flow battery

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB951651A (en) 1960-02-17 1964-03-11 Shell Res Ltd Substituted benzonitriles, their preparation and compositions containing them
US3278532A (en) 1964-07-06 1966-10-11 Sandoz Ag Dioxybenzothiadiazines
US3857972A (en) 1971-03-10 1974-12-31 Int Flavors & Fragrances Inc Flavoring with an oxocyclic pyrimidine
US3843804A (en) 1971-03-10 1974-10-22 Int Flavors & Fragrances Inc Novel flavoring compositions and processes
LU64388A1 (es) 1971-12-02 1973-07-16
FI54312C (fi) 1972-05-09 1978-11-10 Sumitomo Chemical Co Foerfarande foer framstaellning av tieno-(2,3-d)pyrimidinderivat med avsoendring av urinsyra i urin utoekande
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3960860A (en) 1973-01-08 1976-06-01 International Flavors & Fragrances Inc. 2-Methyl-5,7-dihydrothieno-[3,4d]-pyrimidine
US3966965A (en) 1973-03-23 1976-06-29 American Home Products Corporation Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions
US4036837A (en) 1973-03-23 1977-07-19 American Home Products Corporation 2 Alkoxyoxamoyl-pyrazines
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3960783A (en) * 1974-04-01 1976-06-01 Ciba-Geigy Corporation Novel polymers from s-triazine cyanamide compounds
GB1570494A (en) 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4137325A (en) 1977-03-17 1979-01-30 American Home Products Corporation Antisecretory oxamic acid esters
ZA782648B (en) 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
ES472163A1 (es) 1978-07-28 1979-03-16 Consejo Superior Investigacion Ÿun nuevo procedimiento para la obtencion de 5,5-dioxido de 7-amino-2h-4h-vic-triazolo (4,5-c) (1,2,6) tiadiazinaÿ
IE51802B1 (en) 1979-12-03 1987-04-01 Fujisawa Pharmaceutical Co Quinazoline derivatives,processes for their preparation and pharmaceutical compositions containing them
JPS5951290A (ja) 1982-09-14 1984-03-24 Dai Ichi Seiyaku Co Ltd ベンゾチエノイミダゾピリミジンジオン化合物
ES8507558A1 (es) 1984-03-30 1985-09-01 Consejo Superior Investigacion Procedimiento para la preparacion de aminociclotiadiazinas
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4672116A (en) 1985-12-20 1987-06-09 Ortho Pharmaceutical Corporation Substituted 5,6-dialkoxyquinazoline derivatives
JPS6387959A (ja) 1986-10-01 1988-04-19 Sanyo Kokusaku Pulp Co Ltd ステビア甘味料の呈味性改善法
US4960870A (en) 1987-02-11 1990-10-02 Ciba-Geigy Corporation Heavy metal complex azo dyes containing a benzothiophene-1,1-dioxide, 2,1-benzothiazine-2,2-dioxide, 1,4-benzothiazine-1,1-dioxide or thienopyridine-1,1-dioxide coupling component
AU617121B2 (en) 1987-07-17 1991-11-21 Nutrasweet Company, The Substituted guanidines containing a tetrazolyl moiety and their use as high potency sweetening agents
US5380541A (en) 1987-08-07 1995-01-10 Tate & Lyle Public Limited Company Sucralose compositions
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
JPH02238856A (ja) 1989-03-14 1990-09-21 Mitajiri Kagaku Kogyo Kk ミラクリンを有効成分とする矯味・調味料及びこれを含有する飲食品
US5192785A (en) 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
US5504095A (en) 1990-09-19 1996-04-02 Pfizer Inc. Aminobenzosultam derivatives as lipoxygenase inhibitors
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
IL102764A0 (en) 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9127188D0 (en) 1991-12-21 1992-02-19 Smithkline Beecham Plc Novel compounds
KR970010069B1 (ko) 1992-08-24 1997-06-20 주식회사 럭키 신규 세팔로스포린계 항생제 및 이의 제조방법
EP0814861B1 (en) 1995-03-14 2002-06-05 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosing unit
AU690438B2 (en) 1995-03-14 1998-04-23 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosating unit
US6046206A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
DE19632423A1 (de) 1996-08-12 1998-02-19 Merck Patent Gmbh Thienopyrimidine
ES2212816T3 (es) 1996-12-20 2004-08-01 NUTRINOVA NUTRITION SPECIALTIES & FOOD INGREDIENTS GMBH Procedimiento para el refuerzo del poder edulcorante y para el mejoramiento del sabor de una mezcla de materiales edulcorantes muy intensos.
KR100220953B1 (ko) 1996-12-31 1999-10-01 김영환 아미드 또는 이미드를 도입한 ArF 감광막 수지
GB9711650D0 (en) 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
US5954047A (en) 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
US5990117A (en) 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
KR20010052450A (ko) 1998-05-28 2001-06-25 파커 휴우즈 인스티튜트 뇌종양 치료를 위한 퀴나졸린
US6169118B1 (en) 1998-11-12 2001-01-02 Block Drug Company, Inc. Flavor blend for masking unpleasant taste of zinc compounds
AU5213300A (en) 1999-05-19 2000-12-12 Smithkline Beecham Plc 2-nh-pyridones and pyrimidones as mrs inhibitors
GB9915995D0 (en) 1999-07-09 1999-09-08 Ahmed S Non-steroidal sulphamate compounds for use as oestrone sulphatase inhibitors
JP3523166B2 (ja) 1999-09-02 2004-04-26 高砂香料工業株式会社 食品香料劣化防止剤、食品香料劣化防止方法およびその食品香料劣化防止剤を含有する食品
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
MXPA02009843A (es) 2000-04-07 2004-09-06 Senomyx Inc Receptores t2r del sabor y genes que codifican para los mismos.
TW201022287A (en) 2001-01-03 2010-06-16 Senomyx Inc T1R taste receptors and genes encoding same
AU2002233708B2 (en) 2001-03-02 2007-02-08 Nissan Chemical Industries, Ltd. Process for producing quinoline-3-carboxylic acid compound
US7368285B2 (en) 2001-03-07 2008-05-06 Senomyx, Inc. Heteromeric umami T1R1/T1R3 taste receptors and isolated cells that express same
WO2003001876A2 (en) 2001-06-26 2003-01-09 Senomyx, Inc. T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds
WO2003004992A2 (en) 2001-07-03 2003-01-16 The Regents Of The University Of California Mammalian sweet and amino acid heterodimeric taste receptors
US20060134693A1 (en) 2001-07-06 2006-06-22 Guy Servant Olfactory cyclic nucleotide-gated channel cell-based assays to identify T1R and T2R taste modulators
EP1415545B1 (en) 2001-07-19 2006-01-25 San-Ei Gen F.F.I., Inc. Flavor-improving compositions and application thereof
US7115741B2 (en) 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
WO2003051878A1 (en) 2001-12-14 2003-06-26 Merck Frosst Canada & Co. Quinolinones as prostaglandin receptor ligands
AU2002361846A1 (en) 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
US20040127435A1 (en) 2002-08-02 2004-07-01 Regents Of The University Of California Uses for inhibitors of inosine monophosphate dehydrogenase
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
DE10324548A1 (de) 2003-05-28 2004-12-16 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Diätisches Lebensmittel bei einer gewichtskontrollierenden bzw. gewichtsreduzierenden Ernährung
AU2004263871B2 (en) 2003-08-06 2011-07-14 Senomyx, Inc. T1R hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds
WO2005016889A1 (en) 2003-08-08 2005-02-24 Virginia Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties
US20050196503A1 (en) 2004-03-05 2005-09-08 Sunil Srivastava High-intensity sweetener-polyol compositions
AU2005247858A1 (en) 2004-04-14 2005-12-08 Monell Chemical Senses Center Taste receptors of the T1R family from domestic dog
EP1765810B1 (en) 2004-06-08 2016-08-17 Families of Spinal Muscular Atrophy 2,4-diaminoquinazolines for the treatment of spinal muscular atrophy
US20060045953A1 (en) 2004-08-06 2006-03-02 Catherine Tachdjian Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
BRPI0517419A (pt) 2004-10-15 2008-10-07 Ajinomoto Kk composição adoçante, bebida, alimento, composição para cavidade bucal ou produto farmacêutico, estabilizador de conservação para monatina ou um sal da mesma, métodos de conservação de monatina ou de um sal da mesma e de composição adoçante, bebida, alimento, composição para cavidade bucal ou produto farmacêutico compreendendo monatina ou um sal da mesma, e, monatina ou um sal da mesma
US20080261823A1 (en) 2004-12-10 2008-10-23 Yitzhak Tor Fluorescent Nucleoside Analogs That Mimic Naturally Occurring Nucleosides
BRPI0519521A2 (pt) 2004-12-17 2009-02-10 Hoffmann La Roche derivados de tieno-piridina como aumentadores alostÉricos gaba-b
AU2006210513C1 (en) 2005-02-04 2012-10-25 Senomyx, Inc. Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
TW200638882A (en) 2005-02-04 2006-11-16 Senomyx Inc Molecules comprising linked organic moieties as flavor modifiers for comestible compositions
US8796441B2 (en) 2005-04-13 2014-08-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human sweet and umami taste receptor variants
EP1874753A2 (en) 2005-04-14 2008-01-09 Smithkline Beecham Corporation Compounds, compositions and methods
AR055329A1 (es) 2005-06-15 2007-08-15 Senomyx Inc Amidas bis-aromaticas y sus usos como modificadores de sabor dulce, saborizantes, y realzadores de sabor
JP2007007591A (ja) 2005-07-01 2007-01-18 Mikuni Corp 電解水及びその製造方法
CN101277939A (zh) 2005-09-09 2008-10-01 布里斯托尔-迈尔斯斯奎布公司 无环ikur抑制剂
JP5342878B2 (ja) 2005-10-20 2013-11-13 セノミクス・インコーポレーテッド キメラヒト甘味‐旨味および旨味‐甘味味覚受容体
US8506956B2 (en) 2005-10-31 2013-08-13 Kaneka Corporation Method for stabilizing reduced coenzyme Q10
KR20080079673A (ko) 2005-12-22 2008-09-01 아스트라제네카 아베 퀴나졸린 유도체, 이의 제조 방법 및 항암제로서의 이의용도
WO2008003378A1 (de) 2006-07-05 2008-01-10 Merck Patent Gmbh Sulfamat-benzothiophen-derivate
AU2007288220A1 (en) 2006-08-22 2008-02-28 Redpoint Bio Corporation Heterocyclic compounds as sweetener enhancers
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
WO2009006722A1 (en) 2007-07-12 2009-01-15 Mehrzad Gomari Paper-free local flyer advertising (a technology method of localized internet advertising)
EP3085699B1 (en) * 2008-07-31 2022-03-02 Firmenich Incorporated Processes for making sweet taste enhancers
US8609173B2 (en) 2008-07-31 2013-12-17 Senomyx Inc. Compositions comprising sweetness enhancers and methods of making them
US8592592B2 (en) 2010-04-02 2013-11-26 Senomyx, Inc. Sweet flavor modifier
US20130084379A1 (en) 2010-06-29 2013-04-04 Firmenich Sa Active ingredient delivery system
CN106107406B (zh) 2010-08-12 2020-06-09 弗门尼舍公司 提高甜味增强剂的稳定性的方法和包含稳定的甜味增强剂的组合物
CA2815025A1 (en) 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
JP6551936B2 (ja) * 2012-08-06 2019-07-31 セノミックス インコーポレイテッドＳｅｎｏｍｙｘ， Ｉｎｃ． 甘味香味修飾因子
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة

Also Published As

Publication number Publication date
US9603848B2 (en) 2017-03-28
AR110055A2 (es) 2019-02-20
AR110053A2 (es) 2019-02-20
US20080306093A1 (en) 2008-12-11
AR110054A2 (es) 2019-02-20

Similar Documents

Publication Publication Date Title
AR110056A2 (es) Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos
DOP2015000264A (es) Derivados de azaadamantano y métodos de uso de los mismos
CO6150138A2 (es) Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc
NO20071880L (no) Diagnostic Compounds
EA201100875A1 (ru) Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов
CR9786A (es) Compuestos de bencimidazol-tiofeno
CR10157A (es) Compuestos químicos
ECSP10010722A (es) Compuestos orgánicos
MX2015011311A (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y analogos del mismo como inhibidores de atotaxina.
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
EA201000395A1 (ru) Фунгицидные производные 2-алкилтио-2-хинолинилоксиацетамида
ECSP099225A (es) Compuestos antagonistas del receptor de glucagón, composiciones que contienen dichos compuestos y procedimientos de uso
EA201000269A1 (ru) Новые гербициды
EA201000272A1 (ru) Трициклические мостиковые производные циклопентадиенона, как гербициды
EA201170132A1 (ru) 5-гетероциклилалкил-3-гидрокси-2-фенилциклопент-2-еноны в качестве гербицидов
UY31688A1 (es) Plaguicidas
AR112787A2 (es) Compuestos 1,5-difenil-penta-1,4-dien-3-ona
UA106880C2 (uk) Нові гербіциди
UY30451A1 (es) 18-metil-19-nor-androst-4-en-17,17-espiroéteres (18-metil-19-nor-20-espirox-4-en-3-onas),ase como preparaciones farmacéuticas que lo contienen.
MX2010002245A (es) Derivados de ariloxiacetamida bi o triciclicos, saturados e insaturados y su uso como fungicidas.
EA201101097A1 (ru) Новые микробиоциды
NI201800065A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento de cáncer
EA201000069A1 (ru) Новые гербициды
UY30087A1 (es) Piperazinas y piperidinas como potenciadoras de mglur5

Legal Events

Date Code Title Description
FB Suspension of granting procedure